Research Roundtable: Next Frontiers in Cancer Immunotherapy

Watch the on-demand research roundtable hosted by The Scientist, featuring Sean Porazinski, PhD, Head of Scientific Programs at Inventia Life Science.

Why do some tumors respond to immunotherapy while others resist treatment? Differences in tumor biology and the complex interactions within the tumor microenvironment continue to challenge the development and evaluation of cancer immunotherapies.

In this expert roundtable, researchers explore emerging approaches to understanding immunotherapy response and resistance, including molecular profiling, tumor-specific neoantigens, immune cell interactions, and cell-based therapies. The discussion also examines challenges in preclinical immunotherapy research and opportunities to translate molecular insights into improved therapeutic strategies.

What you'll learn:

• How molecular profiling can reveal mechanisms of immunotherapy response and resistance
• Approaches to characterizing the tumor microenvironment and identifying therapeutically relevant neoantigens
• Emerging strategies and research considerations in cell therapy development
• Challenges in preclinical immunotherapy research and opportunities to improve translation

Panelists:

• Sean Porazinski, PhD, Head of Scientific Programs, Inventia Life Science
• William Williams, MD, President and CEO, BriaCell Therapeutics
• Nathan Goodyear, MD, Integrative Medicine Physician, Williams Cancer Institute

Complete the form below to watch the on-demand discussion.